INTRODUCTION
In 2009, a new influenza A (H1N1) virus epidemic broke out in humans worldwide. This virus spread easily amongst humans and resulted in infections in a large number of individuals. Fortunately, the mortality was not high (Garten et al., 2009; Neumann et al., 2009) . The influenza A (H5N1) virus also poses a huge threat to humans; the virus has high mortality in humans, but transmission amongst humans is difficult and it has not caused a pandemic (Sambhara & Poland, 2010) .
In addition, in March of 2013, the first influenza A (H7N9) virus human infection occurred in China (Gao et al., 2013) . So far, a total of 355 individuals have been confirmed with H7N9 infection, with 112 fatalities (WHO, 2014 ). There has not been any solid evidence to demonstrate that H7N9 is capable of human-to-human transmission. However, given the high mutation rates of influenza viruses, it is possible that an influenza virus with high mortality and high transmissibility will re-emerge with disastrous consequences for humans.
Currently, the most effective method for preventing influenza virus infection is influenza vaccination. The influenza virus surface proteins haemagglutinin (HA) and neuraminidase (NA) are the most important antigens for eliciting immune responses (Johansson et al., 1989) . We have reported that in mouse models, DNA vaccines based on influenza virus HA and NA proteins could provide good protection against the homologous influenza virus, and the protective effects were better than for other influenza viral proteins (Chen et al., 1998 (Chen et al., , 2000 . However, influenza virus vaccines based on HA and NA have limited protection against heterologous viruses. The influenza virus nucleoprotein (NP) and matrix (M1 and M2) proteins are highly conserved, and vaccines based on IP: 54.70.40.11
On: Fri, 07 Dec 2018 00:26:18 these proteins showed some protection against heterologous influenza viruses in mouse models (Epstein et al., 2005; Guo et al., 2010; Neirynck et al., 1999; Sui et al., 2010a, b) . Existing influenza vaccines mainly rely on HA and NA of influenza viruses. The World Health Organization must regularly change vaccine composition in response to immune escape of HA and NA proteins (Carrat & Flahault, 2007) , which not only increases the burden of vaccine production, but also places people in a passive position in the face of new influenza viruses.
Previously, it has been reported that influenza virus infection could result in cross-protection. For example, H3N2 infection of mice could induce protective immunity against H5N1 (Kreijtz et al., 2009) . In another study, infection of mice with H1 and H3 influenza viruses could protect them against a challenge by the heterologous 2009 H1N1 A/CA/ 04/09 influenza virus, and it has been demonstrated that the protection was mediated by T-cell immunity (Guo et al., 2011) . In addition, cross-protection mediated by T-cell immunity against influenza viruses has also been confirmed in pigs, chickens, ducks and ferrets (Carter et al., 2013; Fereidouni et al., 2009; Heinen et al., 2001; Seo & Webster, 2001 ).
In the present study, we demonstrated in a mouse model that vaccination with a DNA vaccine of the influenza virus NA gene could not only protect mice against infection by the homologous influenza virus, but also protect against infection by a second, heterologous influenza virus. However, vaccination with a DNA vaccine of the influenza virus HA gene offered limited protection against infection of a second, heterologous influenza virus. These results suggested that NA, a major antigen of influenza virus, could be used as an important candidate antigen for universal influenza vaccines.
RESULTS
Protection of DNA vaccines based on PR8 HA, NA and HA+NA against infection with a lethal dose of PR8
Mice were divided into eight groups. The group names, vaccination contents and schedule, and challenge schedule are given in Table 1 . On days 3 and 5 after PR8 infection, mice lung lavage fluids were collected for virus titre detection. The survival rates for the HAP, NAP and HNP groups were all 100 % (Table 2) , and no symptoms of influenza virus infection were observed. All of the C1 group mice died within 10 days post-infection. For the lung virus load at day 3 post-infection, no influenza virus was detected in Madin-Darby canine kidney (MDCK) cells using lung lavage fluid from the HAP and HNP groups, whilst lung virus titres for the NAP and C1 groups were 1.4±0.1 and 4.35±0.35 log 10 TCID 50 ml
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, respectively, although the titre in the NAP group was significantly lower (P,0.01). For the lung virus load at day 5 post-infection, no influenza virus was detected for the HAP, HNP and NAP groups, whilst the C1 group still had a high virus titre.
Humoral and cellular immune responses before the second, heterologous influenza virus infection
At 2 months after PR8 infection, mouse sera were collected, and antibodies for NP, M1, M2, HA and NA were measured. NP antibody could be detected in all groups with PR8 infection (Table 3 ). The NP antibody titre was as high as 2 15±0.96 in the NAP group, and was only 2 8±1 and 2 7±0.82 in the HAP and HNP groups, respectively; the NP antibody level in the NAP group was significant higher than that in the HAP group (P,0.01). Moreover, M1 and M2 antibodies were detectable in the HAP, NAP and HNP groups, although the titre in the NAP group was significantly higher (P,0.01) than that in the other groups.
For HA antibody, similar levels were found in the HA, HN, HAP and HNP groups, indicating anti-HA titres in the HAP and HNP groups did not rise 2 months after PR8 infection. A high HA antibody titre was also detected in the NAP group.
For NA antibody, similar levels were found in the NA, HN, NAP and HNP groups, indicating that, similar to HA antibody, anti-NA titres in the NAP and HNP groups did not rise 2 months after PR8 infection. The anti-NA titres in the HAP group before and after PR8 infection were 0 and 2 4.5±0.5 , respectively.
Moreover, before the second virus challenge, cellular immune responses were evaluated by detecting IFN-c secretion by mouse lymphocytes from different groups under stimulation by NP and M1 cytotoxic T-lymphocyte (CTL) epitopes (Fig. 1) . The highest level of IFN-c secretion was observed in the NAP group, which was significantly higher than any of the other groups (P,0.01).
In addition, the IFN-c secretion level was higher in the HAP and HNP groups than in the unimmunized and uninfected group (the control group), whereas the HA, NA and HN groups had levels similar to the control group.
Protection against challenge by a second, heterologous influenza virus A/reassortant/ NYMC X-179A (pH1N1)
At 2 months post PR8 infection, mice in all groups except C1 were given a lethal infection of 20 LD 50 A/reassortant/ NYMC X-179A (pH1N1). Lung virus titre was determined on day 3 post-infection for five mice in each group; survival and weight loss were observed continuously for 21 days post-infection.
The survival data are shown in Table 4 and Fig. 2 . All the mice in the C2a group died within 7 days. The three groups without a previous PR8 infection (HA, NA and HN) had survival rates of 20, 50 and 80%, respectively; whereas the three groups with a previous PR8 infection (HAP, NAP and HNP) had survival rates of 30, 100 and 80 %, respectively. The survival rates in the NA, HN, NAP and HNP groups were significantly higher (P,0.05) than that in the C2a group. Moreover, the lung virus titres for the NA, HN, NAP and HNP groups were significantly lower (P,0.05) than that in the C2a group (Table 5 ). The lowest body weight loss was observed in the NAP group (Fig. 3 ).
These results suggested that vaccination with a PR8 NA DNA vaccine provided good protection against pH1N1, and the best protection was seen in mice vaccinated with a PR8 NA DNA vaccine and then recovered from a PR8 infection.
As PR8 and pH1N1 belong to the same subtype (H1N1), we next explored the protective immunity of these genevaccinated and PR8-infected mice in the same experimental procedure using strains of different subtypes (H5N1, H3N2 and H9N2) as the second, heterologous challenge virus. (Table 4) . Only the NAP group had a significantly higher survival rate than the C2b group (P,0.01). Moreover, the NAP group had the lowest lung virus titre (Table 5) , which was significantly lower than Table 1 . Experimental groups and procedure
The mice were divided into eight groups. They were immunized with one (30 mg) or two (30 mg each, 2 weeks apart) DNA vaccines as indicated. The C1 and C2 groups were, respectively, the control groups for the first and the second influenza virus infection, and the C2 group collectively refers to the control group that consisted of C2a (H1N1), C2b (H5N1), C2c (H3N2) and C2d (H9N2). At 1 week after the second immunization, the HAP, NAP, HNP and C1 groups were infected with 20 LD50 PR8 influenza virus; and at 2 months after PR8 infection they were infected with a second, heterologous influenza virus. See Methods for further details.
Group Vaccination First infection (PR8)
Second infection (pH1N1, H5N1, H3N2 or H9N2) HA NA Table 2 . Humoral immune responses pre-PR8 challenge, and lung viral load and survival rates post-PR8 challenge
Groups of mice were immunized according to Table 1 . One week after the second immunization, blood was taken from the mice via the tail vein. Anti-HA or anti-NA titres were determined by HA inhibition (HI) or NA inhibition (NI) assays, respectively. At the same time point, the mice (HAP, NAP, HNP and C1 groups) were infected with 20 LD 50 PR8. At days 3 and 5 post-infection, lung lavage fluid was collected from each group and virus load was measured with MDCK cells. The survival rate was determined on day 21 after challenge. See Methods for further details. Data are presented as mean±SD. that observed in the C2b group (P,0.01). The NAP group also had the lowest maximum weight loss percentage (Fig. 3 ).
These results demonstrated that mice immunized with a PR8 NA DNA vaccine and subsequently infected with a PR8 virus had the best protective immunity against H5N1. The protection might be attributed to two factors. On the one hand, the PR8 NA DNA vaccine offered some protection against the H5N1 virus; on the other hand, the NAP group had strong immune responses to internal conserved proteins of influenza viruses.
Protection against challenge by a second, heterologous influenza virus A/Guizhou/54/ 89¾A/PR /8/34 (H3N2)
Lethal infection with 20 LD 50 A/Guizhou-X (H3N2) was carried out in the seven groups (all but C1) outlined in Table  1 . Improvements in survival rates were found in the DNA vaccine plus PR8 infection groups compared with DNA vaccine only, i.e. HAP .HA, NAP .NA and HNP .HN. A significant difference in survival was found between the NAP group (80 %) and the NA group (10 %) (P,0.01) ( Table 4) . A significant difference in lung virus load was found between NAP group and C2c group (P,0.01) ( Table 5 ).
These results indicated that a PR8 NA DNA vaccine offered poor protection against a non-N1 influenza virus; however, protection could be improved greatly with an additional infection of the homologous virus.
Protection against challenge by a second, heterologous influenza virus A/Chicken/Jiangsu/ 7/2002 (H9N2)
To further verify protection against heterologous influenza viruses observed in the NAP group, A/Chicken/Jiangsu/7/ 2002 (H9N2) was used to carry out the second, heterologous influenza virus infection. Following a lethal H9N2 infection, the survival rate in the NAP group was 90 %, whilst the survival rates in the HA, NA and HN groups were 10, 10 and 20 %, respectively (Table 4) . Moreover, the NAP group also had the lowest lung virus titre (Table 5) and weight loss percentage (Fig. 3) . These results further illustrated that the NAP group had good protection against an influenza virus that was very different to PR8.
DISCUSSION
The most effective prevention for influenza is vaccination. HA and NA are the major antigens of influenza virus. Antibodies against HA could block the initiation of influenza virus infection (Couceiro et al., 1993; Gambaryan et al., 1995) and antibodies against NA could prevent budding of progeny viruses from infected cells (Johansson et al., 1989) . As influenza viruses mutate easily, HA and NA in the influenza vaccine must be consistent with those contained in currently circulating influenza viruses. The experimental design of the present study is based on real-life scenarios. During an influenza outbreak, people will be immunized with the corresponding influenza vaccines; vaccinated individuals are highly likely to encounter infection by a circulating homologous virus, which they are likely to resist due to vaccination. However, will these individuals, vaccinated and then recovered from infection of a homologous influenza virus, gain immunity against a heterologous influenza virus circulating during the next season? The present study addressed this question in a mouse model, and explored the protective effect against a second, heterologous influenza virus in mice first vaccinated with a DNA vaccine of HA and NA (major antigens contained in current influenza vaccines), alone or in combination, and then infected with the homologous influenza virus.
Following immunization with a PR8 HA, NA or HA+NA DNA vaccine, all the mice survived a lethal homologous (PR8) challenge and showed no symptoms of influenza virus infection. On day 3 post-infection, no lung virus titre was detectable for the HA and HA+NA DNA vaccine groups, and the titre detected in the NA DNA vaccine group was significantly lower than that in the control group (P,0.01) and then became undetectable on day 5 post-infection. This difference between the HA and NA DNA vaccine groups might be related to how HA and NA antibodies function. Antibodies to HA could block binding of HA with sialic acid receptors on target cells and block fusion of influenza virus with the cell membrane, thus inhibiting the initiation of virus infection, whereas antibodies to NA could mainly inhibit the activity of NA and prevent the release of progeny virus from infected cells, thereby inhibiting further infections. Both antibodies could effectively inhibit influenza virus infection; however, different mechanisms of the two antibodies result in differences in duration of influenza virus presence in the host and differences in subsequent immune responses.
At 2 months after PR8 infection and before the second challenge, antibody titres for HA, NA, NP, M1 and M2, as well as IFN-c secretion by mouse lymphocytes under stimulation with NP and M1 CTL epitopes were measured. Before and after PR8 infection, high HA antibody titres were observed in the HAP, HNP and NAP groups, but a significant increase was only detected in the NAP group. High NA antibody titres were found in the NAP and HNP groups. Furthermore, we detected NP, M1 and M2 antibodies in all three groups, i.e. HAP, NAP and HNP, but the highest level was found in the NAP group. The level of induced cellular immunity against NP and M1 showed a trend consistent with that seen in antibody levels, and the highest lymphocyte IFN-c secretion under CTL epitope stimulation was found in the NAP group. These changes in immune responses following PR8 infection prompted us to further explore how these different groups of mice might resist challenge by heterologous influenza viruses.
At 2 months after PR8 infection, mice were infected with a lethal dose of influenza virus A/reassortant/NYMC X-179A (pH1N1), a virus of the same subtype as PR8. Amongst all seven groups, the only group with 100 % survival was the NAP group, i.e. mice that had first received a PR8 NA DNA vaccine and then a PR8 virus infection, and the group had the lowest lung virus titre. Meanwhile, survival in both the HNP and HN groups reached 80 %. These results might be related to the fact that HA and NA sequence homologies between PR8 and pH1N1 are 80.7 and 80.8 %, respectively. From the survival data after pH1N1 challenge, we found higher cross-protection in the PR8 NA DNA vaccine groups than in the PR8 HA DNA vaccine group. To further At the same time, we found the HAP group had higher survival than the HA group, which, according to the immune parameters examined, might be due partly to NA antibodies produced in the HAP group after PR8 infection, and to antibodies to NP, M1 and M2; cellular immunity to NP and M1 in the HAP group might also help in the resistance to H5N1 virus. For the HN and HNP groups, both had received the PR8 NA DNA vaccine and had survival rates similar to the NA group. It is worth noting that the survival of the NAP group reached 90 %.
Comparison with the HAP group revealed that both groups produced antibodies to NA, NP, M1 and M2, as well as cellular immunity for NP and M1; however, the antibody levels for NP, M1 and M2 in the NAP group were markedly higher than the other groups, which might be the reason that the NAP group had higher survival than all the other groups. Will the protection remain high if the virus in the second, heterologous infection is a non-N1 subtype influenza virus? To answer this question, we next carried out similar experiments using one of two viruses, A/Guizhou-X (H3N2) and A/Chicken/Jiangsu/7/2002 (H9N2), as the second, heterologous challenge virus.
Mice with either the PR8 HA or NA DNA vaccine but no PR8 infection had almost no resistance to the H3N2 and H9N2 viruses (10 % survival), which reflects the immune escape phenomenon as a result of the antigenic drift and antigenic shift of influenza viruses. However, mice in the NAP group infected with H3N2 or H9N2 had survival rates of 80 and 90 %, respectively, and both rates were significantly higher than the other groups (P,0.01). As antibodies to NA and HA induced by PR8 antigens offer little protection against H3N2 and H9N2, the high protection in the NAP group against H3N2 and H9N2 is likely to be derived mainly from immune responses to NP, M1 and M2. We detected strong immune responses to NP, M1 and M2 in the NAP group, including both humoral and cellular immune responses. Many in vitro murine experiments have demonstrated that CD4 + and CD8 + T-cell-mediated immune responses targeting conserved antigens of an influenza virus could provide cross-protection against different subtypes or variants of the same subtype (Effros et al., 1977; Furuya et al., 2010; Haanen et al., 1999; Liang et al., 1994) , and such immune responses also play important roles in human populations, which has been supported by direct and indirect evidence (Epstein, 2006; McMichael et al., 1983) . Moreover, in vivo knockout experiments for mouse CD4 + and CD8 + T-cells have also confirmed that Tcell immune responses offer cross-protection for influenza viruses (Guo et al., 2011) . In addition, humoral immunity should be a factor contributing to the high protection in the NAP group mice. As well as NA antibodies, anti-M and anti-NP antibodies also played a role. We have found previously that intranasal immunization with NP, M1 or M2 together with appropriate adjuvants could protect 100 % mice against homologous influenza virus, and such protective effect came from the synergy of cell-mediated immunity and humoral immunity (Guo et al., 2010; Sui et al., 2010a, b) . In addition, administration of M2e-specific mAb provided protection against influenza A virus challenge in mice, ferrets and rhesus monkeys models (Fan et al., 2004) . Moreover, Ozawa et al. (2011) showed recently that anti-M2e antibody isolated from human peripheral blood has potential for treating influenza virus infections. NP antibodies have also been shown to have an anti-influenza virus effect (LaMere et al., 2011), whereas there is not yet any direct evidence to show that M1 antibodies have an anti-influenza effect.
Based on the survival data of the groups of mice challenged by one of four second, heterologous influenza viruses, we arrived at the preliminary conclusion that mice immunized with a PR8 NA DNA vaccine and then infected with PR8 virus could be highly protected against a variety of subtypes of influenza viruses. The high protection might be due to the actions of multiple factors. In a previous study, we compared the ability of plasmid DNA encoding various influenza viral proteins to provide protection against lethal viral infections. The results suggested that both HA and NA DNA were highly protective against homologous infection; the M1-and NP-expressing DNA provided partial protection, and the mixture of M1 and NP plasmids protected 95 % of the mice against the homologous H5N1 virus and 80 % of the mice against a heterologous H1N1 (PR8) virus ).
Studies comparing NA of different influenza virus subtypes revealed that amino acid sequences of some key functional domains are highly conserved. Some researchers have grouped NA subtypes into three categories: the first category includes N1, N5 and N8; the second category includes N7 and N9; and the third category includes N2.
Inter-category homology for NA of different subtypes is 40-46 %, intra-category homology for NA of different subtypes rises to 54-68 %, whilst homology for NA of variants of the same subtype is as high as 90 % (Chen et al., 2000; Colman & Ward, 1985; Harley et al., 1989; Martínez et al., 1983) . Therefore, NAs of strains of the same subtype share higher homology than NAs of strains of different subtypes. As the influenza NA gene faces less immune pressure than the HA gene during evolution, NA has been considered an important candidate antigen for universal influenza vaccines by more and more researchers. The cross-protection potential of NA has been confirmed by experiments. In our previous studies, immunization with a DNA vaccine of H3N2 NA could protect against a lethal challenge of homologous virus or a variant of the same subtype; however, it could not protect against a H1N1 virus which belonged to a different subtype. . The number of mice used for observing the survival rate was 10 in each group. *Significantly different from the control group (C2a, C2b, C2c and C2d), P,0.05. Table 5 . Lung virus titre after the second, heterologous influenza virus challenge
On day 3 following the second infection, lung lavage was collect from five mice in each group and lung virus titre was determined using MDCK cells.
Group
Lung virus titre on day 3 after infection (log 10 TCID 50 ml "1 ) same NA serotype, the group of Sandbulte et al. (2007) validated whether immunization with human influenza H1N1 could provide cross-protection against H5N1 and found that a DNA vaccine based on NA of PR8 (H1N1) provided partial cross-protection against a H5N1 virus. Their finding corroborates the results in the present study that NA could be an important candidate antigen in universal influenza vaccines. Therefore, further studies of NA as an important component of universal influenza vaccines are necessary in order to improve its capacity to provide broad protection. Investigation into the development of a NA-based universal influenza vaccine is currently in progress.
In the present study, we demonstrated in a mouse model that mice vaccinated with a PR8 NA DNA vaccine and then infected with the homologous virus had good crossprotection against a second, heterologous influenza virus, including pH1N1, H5N1, H3N2 and H9N2. However, vaccines based on NP, M1 and M2, i.e. highly conserved influenza virus proteins, have better cross-protection against influenza viruses. Of the three proteins, cellular immune responses to NP and M1, as well as antibody responses to M2, have been considered particularly important.
METHODS
Viruses and mice. Influenza virus strains used in this study were A/ PR/8/34 (PR8) (H1N1), A/reassortant/NYMC X-179A (pH1N1), A/ Chicken/Henan/12/2004 (H5N1), A/Chicken/Jiangsu/7/2002 (H9N2) and A/Guizhou/54/896A/PR/8/34 (A/Guizhou-X) (H3N2). The H9N2 and H5N1 influenza viruses were passaged and adapted in mice as described previously Qiu et al., 2006) . The internal genes of pH1N1 and H3N2 were from the PR8 virus. They were frozen at 270 uC until use. All the experiments were performed in a Biosafety Level 3 containment facility.
Specific-pathogen-free female BALB/c mice (6-8 weeks old) were purchased from the Center for Disease Control and Prevention in The number of mice used for observing the survival rate was 10 in each group.
Hubei Province, China. They were bred and maintained under specific-pathogen-free conditions. All the experimental procedures using mice in this study followed the Chinese Regulations for the Administration of Laboratory Animals.
DNA vaccines and peptides. Plasmids pCAGGSP7/HA and pCAGGSP7/NA were prepared as described previously (Chen et al., 2005) . Briefly, plasmids pCAGGSP7/HA and pCAGGSP7/NA were constructed by cloning the PCR products of the HA and NA genes from the PR8 (H1N1) influenza virus strain into the plasmid expression vector pCAGGSP7. The plasmids were propagated in Escherichia coli XL1-blue bacteria and purified using Qiagen purification kits (QIAGEN-tip 500). The peptide KAVKLYRKLKRE for the M1 protein and the peptide TYQRTRALV for the NP protein, which were used for the IFN-c ELISPOT assay (Saha et al., 2006; Watabe et al., 2001) , were synthesized by Shanghai Sangon Biological Engineering Technology & Services.
Immunization and challenge. The study design used a total of 560 mice: including 195 mice for the HA, NA and HN groups (65 mice in each group), 300 mice for the HAP, NAP, HNP and C1 groups (75 mice in each group) and 65 mice for the C2 (C2a, C2b, C2c and C2d) group of the second infection.
The HA, NA or HN groups were all challenged with four heterologous viruses including pH1N1, H5N1, H3N2 and H9N2, with each group having five mice for the ELISPOT assay 1 day before heterologous virus infection, 10 mice for observing survival rate and five mice for lung virus titration against each heterologous virus.
The HAP, NAP, HNP or C1 groups were all challenged with PR8 virus, with each group having five mice for lung virus titration on the third day after PR8 challenge and five mice for lung virus titration on the fifth day after PR8 challenge. One day before heterologous virus infection, five mice from the HAP, NAP or HNP groups were used for the ELISPOT assay. The remaining 60 mice in the HAP, NAP or HNP groups were challenged with four heterologous viruses including pH1N1, H5N1, H3N2 and H9N2, with each group having 10 mice for observing the survival rate and five mice for lung virus titration against each heterologous virus.
Five mice in the C2 groups were used as control for the ELISPOT assay 1 day before heterologous virus infection. The remaining 60 mice were used as control groups C2a, C2b, C2c and C2d against pH1N1, H5N1, H3N2 and H9N2, respectively, with each group having 10 mice for observing the survival rate and five mice for lung virus titration on the third day after each heterologous virus challenge.
Female mice were immunized with HA or NA plasmid, or a mixture of the two plasmids, dissolved in 50 ml Tris/EDTA buffer at a dose of 30 mg each plasmid. The plasmid was injected into the quadriceps muscle. A pair of electrode needles placed 5 mm apart was inserted immediately into the muscle to cover the DNA injection site and electric pulses were delivered using an electric pulse generator (Electro Square Porator T830M; BTX). Three pulses of 100 V each, followed by three pulses of the opposite polarity, were delivered to each injection site at a rate of 1 pulse s -1 . Each pulse lasted 50 ms (Fang et al., 2008) . Specimens. Five mice in each group were anaesthetized with chloroform and then bled from the heart with a syringe. After bleeding, the mice were incised ventrally along the median line from the xiphoid process to the point of the chin. The trachea and lungs were taken out and washed three times by injecting with a total of 2 ml PBS containing 0.1 % BSA. The lung (bronchoalveolar) lavage fluid was used for virus titration after removing cellular debris by centrifugation (Chen et al., 1998) .
Antibody assay by ELISA. The concentrations of IgG antibodies against PR8 (H1N1) NP, M1 and M2 proteins were measured by ELISA. ELISA was performed sequentially from the solid phase using a series of reagents consisting of (i) NP, M1 and M2 protein prepared as described previously (Guo et al., 2010; Sui et al., 2010a, b) , (ii) serial twofold dilutions of sera from each group of immunized or preimmunized mice, (iii) goat anti-mouse IgG antibody (c-chain specific) (Southern Biotechnology Associates) conjugated with biotin, (iv) streptavidin conjugated with alkaline phosphatase (Southern Biotechnology Associates) and (v) p-nitrophenyl-phosphate. The amount of chromogen produced was measured based on A 405-450 in an ELISA reader (Labsystems Multiskan Ascent). Antibody-positive cut-off values were set as means+2SD of preimmunized sera. Antibody titre was expressed as the highest serum dilution giving a positive reaction.
HA inhibition (HI) assay. The anti-HA antibody titres were measured by HI assay. Sera treated with receptor-destroying enzyme were serially diluted (twofold) in V-shaped 96-well plates. Four haemagglutination units of virus were added to the test and incubated at room temperature for 15 min, followed by addition of 0.5 % red blood cells and incubation at room temperature for 30 min. The HI titre was the reciprocal of the highest serum dilution that completely inhibited haemagglutination (Zheng et al., 2009 ], grown in the allantoic sac of 10-day-old chicken embryos and stored as allantoic fluid suspensions at 270 uC, were employed as enzyme source. The NI assay was carried out by preincubating the enzymes (25 ml) with varying dilutions of antiserum (25 ml) at room temperature for 30 min before the enzyme assay. The enzyme mixtures were then incubated with the substrate solution (50 ml) containing 50 mg fetuin l 21 at 37 uC for 18 h. After cooling to room temperature, 100 ml periodate reagent was added. Following incubation for 20 min, the reaction was stopped by addition of 1 ml arsenite reagent; 2.5 ml thiobarbituric acid was then added and plates were incubated at 99 uC for 10 min. Plates were cooled in a water bath and 4 ml butanol reagent was added. Plates were vortexed and centrifuged for 5 min at 1500 r.p.m.; the upper phase was used for measurement based on A 549 . The NI titre was expressed as the highest serum dilution that resulted in the inhibition of NA activity (WHO, 2002) .
IFN-c ELISPOT assay. Spleen cells were isolated from mice for ELISPOT assay 1 day before the second heterologous virus infection. According to the manufacturer's (U-CyTech) instructions, 96-well PVDF plates (Millipore) were coated with 100 ml rat anti-mouse IFNc antibody (10 mg ml 21 ) in PBS and incubated at 4 uC overnight. The plates were washed three times with sterile PBS, and then blocked with 200 ml blocking solution R and incubated at 37 uC for 1 h. Next, 5610 5 lymphocytes isolated from the spleen cells were added to the wells in triplicate, stimulated with a synthesized influenza virus peptide (2 mg ml
21
) and incubated at 37 uC for 18 h. The lymphocytes were then removed, and 100 ml biotinylated anti-mouse IFN-c antibody was added to each well and incubated at 37 uC for 1 h. Subsequently, 100 ml properly diluted streptavidin-HRP conjugate solution was added and incubated at room temperature for 2 h after washing five times with PBS. Finally, the plates were treated with 100 ml 3-amino-9-ethylcarbazole substrate solution and incubated at room temperature for 20 min in the dark. The reaction was stopped by washing with demineralized water. The plates were air-dried at room temperature and read using an ELISPOT reader (Bioreader 4000; BIOSYS) (Chang et al., 2010) .
Virus titrations. To examine the cytopathic effect, the lung lavage fluids, diluted 10-fold serially starting from a dilution of 1 : 10, were inoculated onto MDCK cells at 37 uC for 2 days. The virus titre of each specimen, expressed as TCID 50 , was calculated by the ReedMuench method. The virus titre in each experimental group was represented by the mean±SD virus titre ml 21 of specimens from five mice in each group (Zhang et al., 2013) .
Statistics. The data from test groups were evaluated by Student's ttest; P,0.05 was considered significant. The survival rates of mice in the test and control groups were compared using Fisher's exact test.
